John Ervin
Rheumatology · Kansas City, MONPI 1376565549
Payments from drug & device makers
Across 3,566 payments — averaging $5257.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Emergent Biosolutions Inc.$3.3M
- Merck$2.1M
- Johnson & Johnson$2.1M
- Sanofi Pasteur Inc.$1.9M
- Valneva Austria GmbH$1.8M
- Modernatx, Inc.$1.5M
- plus $5.9M from 27 others
Across 13 payments — averaging $9302.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Valneva Austria GmbH$120K
- Pfizer$866
What the payments were for
- Travel & lodging$1,93588%
- Food & beverage$27612%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Emergent Biosolutions Inc. | 1,899 | $3,334,190 |
| Merck | 115 | $2,143,244 |
| Johnson & Johnson | 42 | $2,129,013 |
| Sanofi Pasteur Inc. | 83 | $1,900,909 |
| Valneva Austria GmbH | 32 | $1,842,972 |
| Modernatx, Inc. | 418 | $1,511,592 |
| Janssen Research & Development, LLC | 71 | $912,908 |
| GSK | 273 | $802,468 |
| Astrazeneca UK Limited | 2 | $732,114 |
| Seqirus USA Inc | 380 | $554,984 |
| Eisai Inc. | 35 | $451,048 |
| Pacira Therapeutics, Inc. | 2 | $395,233 |
| Bavarian Nordic A/s | 23 | $376,596 |
| Vivus LLC | 10 | $281,741 |
| Biontech SE | 14 | $257,920 |
| Boehringer Ingelheim | 3 | $195,128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $194,962 |
| Regeneron | 30 | $183,338 |
| Novartis | 5 | $126,378 |
| Abbott | 42 | $105,140 |
| Vertex | 1 | $94,567 |
| Teva Pharmaceuticals USA, Inc. | 14 | $44,319 |
| Organon | 18 | $38,553 |
| Biohaven Pharmaceuticals, Inc. | 11 | $36,165 |
| Astrazeneca AB | 6 | $31,881 |
| Avanir Pharmaceuticals, Inc. | 4 | $18,054 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 2 | $13,912 |
| Boehringer Ingelheim International GmbH | 2 | $11,235 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $8,335 |
| Pfizer | 3 | $6,696 |
| Sanofi US Services Inc. | 2 | $5,210 |
| Eli Lilly | 3 | $3,565 |
| AstraZeneca | 8 | $2,176 |
How this compares
$18,746,546 in reported general payments places this provider in the 95th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Kansas City
- Ghaith NoaisehKansas City$1.6M
- Tina ShahKansas City$1.2M
- Mark BoxKansas City$396K
- Thomas ScottKansas City$48K
- David JohnKansas City$3K
- Julian MagadanKansas City$3K
- David TrueSpringfield$15.8M
- Anne WinklerCarthage$1.6M
- Alfred KimSaint Louis$1.2M
- Sona KamatSaint Louis$931K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.